THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

Scientists at Pohang University of Science and Technology (POSTECH) and ShanghaiTech University have achieved a breakthrough ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Patient-derived organoids (PDOs) are revolutionizing cancer research, enhancing drug testing and personalized treatment ...

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

It’s that time of year again! The North Country Festival of Trees is right around the corner. K.I. LaClair and Dawn Atwood ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

News Daybreak has the headlines you need to know to get your Friday started. The Nebraska State Patrol shared more examples ...

December S&P 500 E-Mini futures (ESZ24) are down -0.09%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.14% this morning as investors assessed the potential policy impact of Donald Trump’s ...

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in ...